Bicycle Therapeutics plc - American Depositary Shares (BCYC) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor
NEWS SCORE
50/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
28
Weak based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$4.22
Trend Context
Mixed / range
Latest briefing
What's happening with BCYC
businesswire.com21 May 2026
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of initial data from the randomized Phase 2 trial (Duravelo-2) evaluating zelenectide pevedotin (zelenectide) in previously untreated patients with metastatic urothelial cancer (mUC), demonstrating encouraging response rates and a.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
businesswire.com30 Apr 2026
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the first quarter ended March 31, 2026, and provided recent corporate updates. “The data we reported in the first quarter continues to provide further validation of the potential of our Bicycle technology to deliver oncology th.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
businesswire.com21 Apr 2026
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster presentations across five abstracts at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29–June 2 in Chicago. Presentation Details: Title: Interim analysis results from.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
businesswire.com
20 Apr 2026
Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
